<DOC>
	<DOCNO>NCT02107950</DOCNO>
	<brief_summary>The purpose study determine whether DCVAC/OvCa add chemotherapy ( carboplatin gemcitabine second line chemotherapy ) may result prolongation progression free survival ( PFS ) .</brief_summary>
	<brief_title>Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum ( Pt ) -Sensitive Epithelial Ovarian Carcinoma</brief_title>
	<detailed_description>The purpose study determine whether DCVAC/OvCa add Standard Care chemotherapy ( carboplatin gemcitabine second line chemotherapy ) may result prolongation progression free survival ( PFS ) .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Females 18 year old old Patients histologically confirm , International Federation Gynecology Obstetrics ( FIGO ) stage III IV epithelial ovarian , primary peritoneal fallopian tube carcinoma ( serous , endometrioid mucinous ) , complete remission first line platinum ( Pt ) base chemotherapy select receive second line Standard Care chemotherapy Radiologically confirm relapse &gt; 6 month remission ( Platinumsensitive patient ) , find 4 week prior study entry . The patient must least one measureable target lesion define Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 criterion eligible enrolment study FIGO I , II epithelial ovarian cancer FIGO III , IV clear cell epithelial ovarian cancer Nonepithelial ovarian cancer Borderline tumor ( tumor low malignant potential ) Prior current systemic anticancer therapy ovarian cancer [ example chemotherapy , monoclonal antibody therapy , tyrosine kinase inhibitor therapy , vascular endothelial growth factor ( VEGF ) therapy hormonal therapy ] except first line Platinumbased chemotherapy ( without bevacizumab ) Previous radiotherapy abdomen pelvis Malignancy epithelial ovarian cancer , except clinical remission ( CR ) minimum 3 year , except carcinoma insitu cervix nonmelanoma skin carcinoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Ovarian</keyword>
	<keyword>Platinum Sensitive</keyword>
	<keyword>Epithelial</keyword>
</DOC>